| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
SF-3-030 (2.5-60 μM; 30 min) selectively inhibited ERK2-mediated c-Fos F site-dependent phosphorylation of Thr325 residues in vitro, with no effect on D-domain-containing substrates (RSK1) or p38α-mediated ATF2 phosphorylation [2]. SF-3-030 (1-100 μM; 20 min-5 h) inhibited the activity of AP-1 and SRE promoters in EGF/PMA-stimulated HeLa/HEK293 cells and inhibited basal AP-1 activity in A375 melanoma cells, with stronger inhibitory efficacy against PMA-induced responses than against EGF-induced responses [2]. SF-3-030 (5-100 μM; 30 min-1 h) selectively inhibited the expression of EGF/PMA-induced F-site-containing IEGs (c-Fos, Fra1, FosB, FosB2, c-Myc) in HeLa and A375 cells, with minimal effect on F-site-free IEGs (c-Jun, Egr1) [2]. SF-3-030 (1-100 μM; 24 h) selectively inhibited the proliferation of constitutive ERK1/2-active melanoma cells (A375, RPMI7951) and induced their apoptosis, with GI50 values of 7.1 μM and 4.6 μM, respectively, while also showing selectivity for Jurkat cells (GI50 > 50 μM) [2].
|
|---|---|
| ln Vivo |
SF-3-030 (10 mg/kg; administered 30 minutes before each house dust mite (HDM) stimulation; 5 days a week for 3 weeks) reduced a variety of house dust mite-induced asthma features in mice induced by house dust mite (HDM) [1].
|
| Cell Assay |
Western Blot Analysis [2]
Cell Types: HeLa Cells Tested Concentrations: 5, 10, 20, 35, 40, 70, 100 Incubation Duration: 30 min pretreatment Experimental Results: In EGF-stimulated HeLa cells, the induction of c-Fos, FosB, FosB2, Fra1, and c-Myc was inhibited in a dose-dependent manner. The effect on c-Jun and Egr1 was minimal, and c-Fos phosphorylation at Ser32 in EGF-stimulated HeLa cells was inhibited, but not at Ser374. It inhibited c-Fos phosphorylation at Thr232 and Ser32, but did not inhibit phosphorylation at Ser374, and reduced the expression of FosB, FosB2, Fra1 and c-Myc in PMA-stimulated HeLa cells. Western Blot analysis [2] Cell Types: A375 melanoma cells Tested Concentrations: 5, 25, 35, 50 μM Incubation Duration: 1 hour Experimental Results: Inhibited the basal expression of c-Fos, FosB, FosB2, Fra1 and c-Myc, but did not inhibit Egr1. |
| Animal Protocol |
Animal/Disease Models:Balb/c mice (8-10 weeks old) were stimulated by house dust mite (HDM) [1]
Doses: 10 mg/kg Route of Administration: Administered within 30 minutes before each HDM stimulation; 5 days a week for 3 weeks Experimental Results: Significantly reduced HDM-induced airway inflammation. Inhibited airway remodeling (AR) induced by repeated allergen stimulation. Inhibited the development of HDM-induced airway inflammatory hyperresponsiveness (AHR). Regulated lung tissue gene expression profile. Regulated the expression profile of multiple pathway-related proteins in lung tissue. |
| References |
|
| Molecular Formula |
C14H12O5S2
|
|---|---|
| Molecular Weight |
324.37
|
| CAS # |
1883721-73-0
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=S(=O)(OC1C=CS(=O)(=O)C1)C=2C=CC=3C=CC=CC3C2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | |
| 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
